新辅助化疗联合免疫治疗为袖状肺叶切除术患者带来生存获益
该回顾性研究纳入139例接受袖状肺叶切除术的非小细胞肺癌患者,比较新辅助化疗联合免疫检查点抑制剂与单纯新辅助化疗的长期生存。联合治疗组病理完全缓解率更高(26.3% vs 6.0%,P<0.001),无事件生存(HR 0.37,95%CI 0.16-0.85,P=0.020)和总生存(HR 0.23,95%CI 0.06-0.80,P=0.021)均更优。
要点
- 联合组病理完全缓解率26.3%,单纯化疗组6.0%(P<0.001)。
- 联合组无事件生存HR 0.37(95%CI 0.16-0.85,P=0.020)。
- 联合组总生存HR 0.23(95%CI 0.06-0.80,P=0.021)。
核心结论
- 新辅助ICI联合化疗与接受袖状肺叶切除术的非小细胞肺癌患者良好的长期生存相关。
研究设计与样本
- 回顾性识别接受新辅助ICI联合化疗或新辅助化疗后行支气管袖状肺叶切除术的患者,比较两组治疗反应、围手术期结局、无事件生存和总生存,并在整体队列和逆概率治疗加权调整队列中分析。
- 共纳入139例患者,其中39例肺癌复发和21例死亡;83例(59.7%)接受新辅助化疗,56例(40.3%)接受新辅助ICI联合化疗。
主要发现
- 逆概率治疗加权后,新辅助ICI联合化疗组达到病理完全缓解的患者更多(6.0% vs 26.3%,P < 0.001)。
- 总体术后并发症(23.8% vs 20.2%,P = 0.624)和具体并发症(所有P > 0.05)无显著差异。
- 接受新辅助ICI联合化疗的患者无事件生存更优(HR 0.37,95%CI 0.16-0.85,P = 0.020),总生存也更优(HR 0.23,95%CI 0.06-0.80,P = 0.021)。
- 多变量分析显示,新辅助ICI联合化疗是无事件生存良好的独立预测因素(HR 0.37,95%CI 0.15-0.86,P = 0.020,校正临床TNM分期)。
关键数值与推荐
- 病理完全缓解率:新辅助ICI联合化疗组26.3% vs 新辅助化疗组6.0%(P < 0.001)。
- 总体术后并发症发生率:新辅助ICI联合化疗组20.2% vs 新辅助化疗组23.8%(P = 0.624)。
- 无事件生存:新辅助ICI联合化疗组 vs 新辅助化疗组 HR 0.37(95%CI 0.16-0.85,P = 0.020)。
- 总生存:新辅助ICI联合化疗组 vs 新辅助化疗组 HR 0.23(95%CI 0.06-0.80,P = 0.021)。
- 多变量分析无事件生存:新辅助ICI联合化疗组 vs 新辅助化疗组 HR 0.37(95%CI 0.15-0.86,P = 0.020,校正临床TNM分期)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: It has been demonstrated that neoadjuvant immune checkpoint inhibitor (ICI) plus chemotherapy was safe and feasible referred to neoadjuvant chemotherapy for patients with non-small cell lung cancer undergoing sleeve lobectomy. Nevertheless, no survival data were reported in the previous researches. Therefore, we conducted this study to compare neoadjuvant ICI plus chemotherapy versus neoadjuvant chemotherapy followed by sleeve lobectomy for long-term survival outcomes. METHODS: Patients who underwent bronchial sleeve lobectomy following neoadjuvant ICI plus chemotherapy or neoadjuvant chemotherapy were retrospectively identified. Treatment response, perioperative outcomes, event-free survival and overall survival were compared between groups in the overall and the inverse probability of treatment weighting-adjusted cohort. RESULTS: A total of 139 patients with 39 lung cancer recurrence and 21 death were included. Among them, 83 (59.7%) and 56 (40.3%) patients received neoadjuvant chemotherapy and neoadjuvant ICI plus chemotherapy, respectively. After inverse probability of treatment weighting, more patients achieved complete pathological response in the neoadjuvant ICI plus chemotherapy group (6.0% vs 26.3%, P < 0.001). There was no significant difference regarding overall postoperative complication (23.8% vs 20.2%, P = 0.624) and specific complications (all P > 0.05). Patients receiving neoadjuvant ICI plus chemotherapy had favourable event-free survival (hazard ratio 0.37, 95% confidence interval 0.16-0.85, P = 0.020) and overall survival (hazard ratio 0.23, 95% confidence interval 0.06-0.80, P = 0.021). Multivariable analysis revealed that neoadjuvant ICI plus chemotherapy was an independent predictor for favourable event-free survival (hazard ratio 0.37, 95% confidence interval 0.15-0.86, P = 0.020, adjusted for clinical TNM stage). CONCLUSIONS: Neoadjuvant ICI plus chemotherapy was correlated with favourable long-term survival in patients with non-small cell lung cancer undergoing sleeve lobectomy.
引用
- Chen T, Wen J, He Y, et al. Neoadjuvant chemoimmunotherapy confers survival advantage for patients undergoing sleeve lobectomy. Eur J Cardiothorac Surg. 2024. PMID: 38539042. doi:10.1093/ejcts/ezae125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。